The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery

Pharmacokinetic evaluation is an essential component of drug discovery and should be conducted early in the process so that those compounds with the best chance of success are prioritized and progressed. However, pharmacokinetic analysis has become a serious bottleneck during the ‘hit-to-lead’ and lead optimization phases due to the availability of new targets and the large numbers of compounds resulting from advances in synthesis and screening technologies. Cassette dosing, which involves the simultaneous administration of several compounds to a single animal followed by rapid sample analysis by liquid chromatography/tandem mass spectrometry, was developed to increase the throughput of in vivo pharmacokinetic screening. Although cassette dosing is advantageous in terms of resources and throughput, there are possible complications associated with this approach, such as the potential for compound interactions. Following an overview of the cassette dosing literature, this article focuses on the application of the technique in anticancer drug discovery. Specific examples are discussed, including the evaluation of cassette dosing to assess pharmacokinetic properties in the development of cyclin-dependent kinase and heat shock protein 90 inhibitors. Subject to critical analysis and validation in each case, the use of cassette dosing is recommended in appropriate chemical series to enhance the efficiency of drug discovery and reduce animal usage. [Mol Cancer Ther 2007;6(2):428–40]

[1]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[2]  X. Tong,et al.  High-throughput pharmacokinetics screen of VLA-4 antagonists by LC/MS/MS coupled with automated solid-phase extraction sample preparation. , 2004, Journal of pharmaceutical and biomedical analysis.

[3]  C. Laggner,et al.  Why drugs fail--a study on side effects in new chemical entities. , 2005, Current pharmaceutical design.

[4]  Xavier Barril,et al.  Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. , 2005, Journal of medicinal chemistry.

[5]  R E White,et al.  Pharmacokinetic theory of cassette dosing in drug discovery screening. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[6]  K. Adkison,et al.  Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput. , 1997, Journal of medicinal chemistry.

[7]  D. Brewster,et al.  Trends in cancer incidence and mortality in Scotland: description and possible explanations. , 1998, British Journal of Cancer.

[8]  P. Workman,et al.  Finding the needle in the haystack: why high-throughput screening is good for your health , 2002, Breast Cancer Research.

[9]  P. Griffin,et al.  Determination of brain and plasma drug concentrations by liquid chromatography/tandem mass spectrometry. , 2000, Rapid communications in mass spectrometry : RCM.

[10]  L. Cohen,et al.  Evaluation of online extraction/mass spectrometry for in vivo cassette analysis. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  Martin Vogel,et al.  LC/MS Applications in Drug Development , 2002 .

[12]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[13]  P. Workman How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. , 2003, Current pharmaceutical design.

[14]  E. Kanaoka,et al.  A new generic column switching system for quantitation in cassette dosing using LC/MS/MS. , 2003, Journal of pharmaceutical and biomedical analysis.

[15]  D S Wright,et al.  Sample pooling to expedite bioanalysis and pharmacokinetic research. , 1998, Journal of pharmaceutical and biomedical analysis.

[16]  Walter A. Korfmacher,et al.  HPLC-API/MS/MS : a powerful tool for integrating drug metabolism into the drug discovery process , 1997 .

[17]  Evans,et al.  Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery. , 2000, Drug discovery today.

[18]  P. Workman,et al.  Design and development of signal transduction inhibitors for cancer treatment: Experience and challenges with kinase targets , 2006 .

[19]  H. Zeng,et al.  The investigation and the use of high flow column-switching LC/MS/MS as a high-throughput approach for direct plasma sample analysis of single and multiple components in pharmacokinetic studies. , 2002, Journal of pharmaceutical and biomedical analysis.

[20]  Walter A. Korfmacher,et al.  Rapid determination of pharmacokinetic properties of new chemical entities: in vivo approaches. , 2002, Combinatorial chemistry & high throughput screening.

[21]  N. J. McNally,et al.  United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). , 1998, British Journal of Cancer.

[22]  A. John Bailer,et al.  Testing for the equality of area under the curves when using destructive measurement techniques , 1988, Journal of Pharmacokinetics and Biopharmaceutics.

[23]  Paul Workman,et al.  Pharmacodynamic biomarkers for molecular cancer therapeutics. , 2007, Advances in cancer research.

[24]  M. Drysdale,et al.  Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors , 2006, Molecular Cancer Therapeutics.

[25]  G. Hopfgartner,et al.  Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry. , 2003, Mass spectrometry reviews.

[26]  F. Russel,et al.  Screening for the role of transporters in hepatic and renal drug handling. , 2004, Drug discovery today. Technologies.

[27]  T. Olah,et al.  The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. , 1997, Rapid communications in mass spectrometry : RCM.

[28]  H. Varmus,et al.  Oncogenes come of age. , 2005, Cold Spring Harbor symposia on quantitative biology.

[29]  L. Kuo,et al.  Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library. , 2000, Bioorganic & medicinal chemistry letters.

[30]  Mei-Yi Zhang,et al.  Determination of rat oral bioavailability of soy-derived phytoestrogens using an automated on-column extraction procedure and electrospray tandem mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[31]  Paul Workman,et al.  CHAPTER 14 – MECHANISM-BASED HIGH-THROUGHPUT SCREENING FOR NOVEL ANTICANCER DRUG DISCOVERY , 2002 .

[32]  Sample pooling to enhance throughput of brain penetration study. , 1999, Journal of pharmaceutical and biomedical analysis.

[33]  S. Clarke,et al.  In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202 , 2005, Clinical Cancer Research.

[34]  T. Kennedy Managing the drug discovery/development interface , 1997 .

[35]  J. Yuan,et al.  Estimation of variance for AUC in animal studies. , 1993, Journal of pharmaceutical sciences.

[36]  Sonu Sundd Singh,et al.  Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. , 2006, Current drug metabolism.

[37]  Cox,et al.  Novel procedure for rapid pharmacokinetic screening of discovery compounds in rats. , 1999, Drug discovery today.

[38]  T G Myers,et al.  DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. , 1999, Journal of the National Cancer Institute.

[39]  P. Woollard,et al.  Cassette dosing: rapid in vivo assessment of pharmacokinetics , 1998 .

[40]  D. Lane,et al.  Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. , 2004, Molecular cancer therapeutics.

[41]  S. Lakhani,et al.  Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Sparreboom,et al.  Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination , 2005, Expert opinion on drug metabolism & toxicology.

[43]  P. Workman Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. , 2005, Cold Spring Harbor symposia on quantitative biology.

[44]  T. Olah,et al.  A direct technique for the simultaneous determination of 10 drug candidates in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry interfaced to a Prospekt solid-phase extraction system. , 1997, Journal of pharmaceutical and biomedical analysis.

[45]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[46]  J. Henion,et al.  Atmospheric pressure ionization LC/MS/MS techniques for drug disposition studies. , 1998, Journal of pharmaceutical sciences.

[47]  P. Workman Challenges of PK/PD measurements in modern drug development. , 2002, European journal of cancer.

[48]  Martin R. Johnson,et al.  Discovery of further pyrrolidine trans-lactams as inhibitors of human neutrophil elastase (HNE) with potential as development candidates and the crystal structure of HNE complexed with an inhibitor (GW475151). , 2002, Journal of medicinal chemistry.

[49]  C. Hop,et al.  Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. , 1998, Journal of pharmaceutical sciences.

[50]  K. Adkison,et al.  Use of "N-in-One" dosing to create an in vivo pharmacokinetics database for use in developing structure-pharmacokinetic relationships. , 1999, Journal of pharmaceutical sciences.

[51]  P. Janser,et al.  A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[52]  P. Workman Genomics and the second golden era of cancer drug development. , 2005, Molecular bioSystems.

[53]  M. Kansy,et al.  Advances in screening for membrane permeability: high-resolution PAMPA for medicinal chemists. , 2004, Drug discovery today. Technologies.

[54]  P. Workman,et al.  Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice , 2004, Cancer Chemotherapy and Pharmacology.

[55]  L. Pearl,et al.  High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. , 2004, Analytical biochemistry.

[56]  A. Ungell Caco-2 replace or refine? , 2004, Drug discovery today. Technologies.

[57]  S. Walker,et al.  Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). , 1988, British journal of clinical pharmacology.

[58]  Paul Workman,et al.  The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[59]  Simon A Roberts Drug metabolism and pharmacokinetics in drug discovery. , 2003, Current opinion in drug discovery & development.

[60]  M. Drysdale,et al.  Discovery and development of pyrazole-scaffold Hsp90 inhibitors. , 2006, Current topics in medicinal chemistry.

[61]  W. Day,et al.  Rapid Determination of Oral Pharmacokinetics and Plasma Free Fraction Using Cocktail Approaches: Methods and Application , 2004, Pharmaceutical Research.

[62]  P. Workman,et al.  Gene expression microarray technologies in the development of new therapeutic agents. , 2004, European journal of cancer.

[63]  Ronald E White,et al.  Whatever happened to cassette-dosing pharmacokinetics? , 2004, Drug discovery today.

[64]  K. Subramanian truPK – human pharmacokinetic models for quantitative ADME prediction , 2005, Expert opinion on drug metabolism & toxicology.

[65]  M K Bayliss,et al.  High-throughput pharmacokinetics: cassette dosing. , 1999, Current opinion in drug discovery & development.

[66]  E. Sausville,et al.  Clinical development of 17-allylamino, 17-demethoxygeldanamycin. , 2003, Current cancer drug targets.

[67]  Walter A. Korfmacher,et al.  Novel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats , 1999 .

[68]  M. Lee,et al.  LC/MS applications in drug development. , 2002, Mass spectrometry reviews.

[69]  M. Egorin,et al.  Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. , 1998, Cancer research.

[70]  M. Drysdale,et al.  Inhibitors of HSP90 and other chaperones for the treatment of cancer , 2004 .

[71]  R. Gupta,et al.  A high throughput approach for simultaneous estimation of multiple synthetic trioxane derivatives using sample pooling for pharmacokinetic studies. , 2005, Journal of pharmaceutical and biomedical analysis.

[72]  P. Workman The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones , 2003, Cancer Chemotherapy and Pharmacology.

[73]  S. Potkay,et al.  Frequently asked questions about the public health service policy on humane care and use of laboratory animals. , 2003, Lab animal.

[74]  Walter A. Korfmacher,et al.  Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery. , 2001, Rapid communications in mass spectrometry : RCM.

[75]  L. Benet,et al.  Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[76]  Kiyoshi Hasegawa,et al.  Cassette Dosing Approach and Quantitative Structure-Pharmacokinetic Relationship Study of Antifungal N-Myristoyltransferase Inhibitors , 2002, J. Chem. Inf. Comput. Sci..

[77]  L. Jia,et al.  Simultaneous estimation of pharmacokinetic properties in mice of three anti-tubercular ethambutol analogs obtained from combinatorial lead optimization. , 2005, Journal of pharmaceutical and biomedical analysis.

[78]  D. Lane,et al.  Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. , 2005, Molecular cancer therapeutics.

[79]  R. Riley,et al.  Metabolic screening in vitro: metabolic stability, CYP inhibition and induction. , 2004, Drug discovery today. Technologies.

[80]  J. T. Wu,et al.  Direct plasma sample injection in multiple-component LC-MS-MS assays for high-throughput pharmacokinetic screening. , 2000, Analytical chemistry.

[81]  R. Gupta,et al.  LC fluorescence method for multiple synthetic compounds to rapidly create in vivo pharmacokinetic database utilizing 'N-in-One' dosing. , 2001, Journal of pharmaceutical and biomedical analysis.

[82]  Matthew Segall,et al.  In silico prediction of ADME properties: are we making progress? , 2004, Current opinion in drug discovery & development.